Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
Indapta Therapeutics, INC.
Modality
monoclonal_antibody
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06677710CT.gov IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nervous System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ocrelizumab (this asset) | Indapta Therapeutics, INC. | P1 | CC · 43 |
| Ginkgolide | Second Affiliated Hospital, School of Medicine, Zhejiang University | P4 | BB |
| Guanfacine | Maimonides Medical Center | P4 | BB |
| Brexpiprazole | Otsuka Pharmaceutical Development & Commercialization, Inc. | P3 | BB |
| Live Combined Bifidobacterium,Lactobacillus And Enterococcus Capsules | Beijing Friendship Hospital | P4 | BB |
| D-Thioctic Acid | Ain Shams University | P4 | BB |
| 3-N-BUTYLPHTHALIDE | Qianfoshan Hospital | P4 | BB |
| Live Combined Bifidobacterium | Beijing Friendship Hospital | P4 | BB |
| Egb 761® | Ipsen | P3 | BB |
+42 more in the Nervous System Disorder cohort
Other indications for Ocrelizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 76 |
| Primary Progressive Multiple Sclerosis | — | P4 | BBB · 76 |
| Multiple Sclerosis | — | P4 | BBB · 72 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- GinkgolideSecond Affiliated Hospital, School of Medicine, Zhejiang UniversityBB
- GuanfacineMaimonides Medical CenterBB
- BrexpiprazoleOtsuka Pharmaceutical Development & Commercialization, Inc.BB
- Live Combined Bifidobacterium,Lactobacillus And Enterococcus CapsulesBeijing Friendship HospitalBB
- D-Thioctic AcidAin Shams UniversityBB
Citation
Floatz Terminal. Ocrelizumab in Nervous System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ocrelizumab-nervous-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →